Pipeline

We're tackling diseases where there is a significant patient need for more and better solutions, with our focus on hepatitis C, immune-mediated conditions, cancer and more. Our scientists are working to advance a pipeline of specialty medicines that demonstrate both strong clinical performance and economic value. Our expertise in both small molecules and biologics gives us the flexibility to find and pursue the best solution for a given disease.

Development by Therapeutic Area


Our expertise in both small molecules and biologics allows us to find and pursue the best solution for a given disease.

Oncology
Immunology
Neuroscience
HCV / Liver Disease
Other
Active
Submitted or recently approved
Phase 1 Phase 2 Phase 3
ABBV-838
Multiple Myeloma
 
ABT-199
AML
 
ABT-199
CLL
(Relapsed/Refactory)
ABT-399
Solid Tumors
 
ABT-199
iNHL/DLBCL
 
ABT-199
CLL
(Front-line; Unfit)
ABT-165
Solid Tumors
 
ABT-199
Multiple Myeloma
 
Imbruvica
Pancreatic Cancer
 
RTA-ABT 408
Solid Tumors
 
Duvelisib
iNHL
(R/R)
Imbruvica
DLBCL
(TN)
ABBV-075
Solid Tumors & Hem Onc
 
ABT-414
GBM
 
Imbruvica
FL
(R/R)
ABBV-221
Solid Tumors
 
Imbruvica
Multiple Myeloma
 
Imbruvica
MCL
(TN)
BTK Inhibitor
Autoimmune
 
Imbruvica
AML
 
Duvelisib
CLL
(R/R)
Imbruvica
Solid Tumors
 
Imbruvica
ALL
 
Elotuzumab
Multiple Myeloma
(TN)
ABBV-084
SLE
 
Imbruvica
MZL
(R/R)
Veliparib
NSCLC
(Squamous)
ABBV-672
Alzheimer’s
 
Imbruvica
MZL
(R/R)
Veliparib
NSCLC
(Non-squamous)
ABT-957
Alzheimer’s
 
Imbruvica
Graft V Host
 
Veliparib
Breast Cancer
(Neoadjuvant)
ABBV-8E12
PSP & AD
 
ABT-122
RA
 
Veliparib
Breast Cancer
(BRCA)
ABBV-974
Cystic Fibrosis
 
ABT-122
PsA
 
Veliparib
Ovarian Cancer
 
ABT-494
Crohn’s Disease
 
ABT-494
RA
 
ABT-981
Osteoarthritis
 
ABT-493 / ABT-530
HCV
 
ALX-0061
RA
 
Elagolix
Endometriosis
 
Elagolix
Uterine Fibroids
(Phase III start 1Q16)
Atrasentan
Diabetic Nephropathy
 

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?